EUCTR2011-006017-34-NL进行中（未招募）1 期
A phase Ib dose escalation/randomized phase II, multicenter, open-label study of BYL719 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma - BYL719 and cetuximab in head and neck cancer
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 202
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Patients with histologically/cytologically-confirmed HNSCC
- •- Patients must be resistant to platinum-based chemotherapy, or be ineligible (due to medical comorbidities) or intolerant to platinum-based therapy per medical history
- •- For Phase II, patients may have received a maximum of 1 prior line of therapy for recurrent or metastatic disease
- •- For Phase II, Arms 1 and 2, prior cetuximab or other EGFR-targeted antibody therapy is allowed only if administered in the induction setting, or concurrently with radiation in the curative setting, with the last dose of cetuximab administered at least 12 months prior to starting the study treatment. For Arm 3, prior cetuximab must have been administered in the curative, recurrent or metastatic disease setting and disease progression documented within 9 months of the last dose of cetuximab administered in that setting. This regimen (including both platinum and cetuximab) must be the most recent anti-neoplastic treatment regimen administered.
- •- Patients with swallowing dysfunction who are unable to swallow BYL719 film-coated whole tablets and are not using feeding tubes for study drug administration can participate in the Phase Ib Arm B. For the Phase II, these patients with swallowing dysfunction may participate if able to drink the suspension and results of Arm B confirm the use of this method. Patients with swallowing dysfunction requiring G tube for study drug administration may participate in Phase II if Arm C confirms dispersible tablet via G tube administration is permitted. Both G- and PEG-tubes are allowed in Arm C
- •- Availability of a representative tumor specimen. Patients enrolled in Arm 3 of Phase II must have disease sites amenable to biopsy unless prior agreement between Novartis and the Investigator.
- •- At least one measurable or non-measurable lesion as per RECIST 1.1 criteria for patients in Phase Ib; Measurable disease as determined by RECIST v1.1 for Phase II patients
- •Other inclusion criteria may apply as per protocol
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 120
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 82
排除标准
- •- Prior treatment with PI3K-inhibitors
- •- Patients with a prior serious infusion reaction to cetuximab
- •- Clinically significant cardiac disease or impaired cardiac function
- •- Patients with diabetes mellitus
- •- Impaired GI function or GI disease
- •Other exclusion criteria may apply as per protocol
研究者
相似试验
已完成
不适用
A phase Ib dose escalation/randomized phase II, multicenter, open-label study of BYL719 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinomaHead and neck cancer10027655NL-OMON40123ovartis8
进行中（未招募）
1 期
A clinical study with BYL719 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinomaHead and Neck CarcinomaEUCTR2011-006017-34-FRovartis Pharma Services AG112
已完成
1 期
A Study to Evaluate Safety, Tolerability, and Antiviral Activity of BRII-179 (VBI-2601) amongSubjects with Chronic Hepatitis BACTRN12619001210167Brii Biosciences49
进行中（未招募）
不适用
A PHASE 1B DOSE ESCALATION/PHASE 2 RANDOMIZED, NON-COMPARATIVE, MULTIPLE CENTER, OPEN LABEL STUDY OF CP-751,871 IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN AND OF PACLITAXEL AND CARBOPLATIN ALONE AS FIRST LINE TREATMENT FOR ADVANCED NON SMAL CELL LUNG CANCERAdvanced Non-Small Cell Lung CancerEUCTR2005-002249-38-ESPfizer S.A.156
进行中（未招募）
不适用
A PHASE 1B DOSE ESCALATION/PHASE 2 RANDOMIZED, NON-COMPARATIVE, MULTIPLE CENTER, OPEN LABEL STUDY OF CP-751,871 IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN AND OF PACLITAXEL AND CARBOPLATIN ALONE AS FIRST LINE TREATMENT FOR ADVANCED NONSMALL CELL LUNG CANCER - NDPatients with Stage IIIB or Stage IV or recurrent non-small cell lung cancer who have received no prior chemotherapy for their disease.MedDRA version: 6.1Level: PTClassification code 10029521EUCTR2005-001224-36-ITPFIZER190